Mayo Clinic and Thermo Fisher Scientific have launched Precure, a joint venture to analyze one million biospecimens using multi-omics data and AI for early disease biomarker discovery.
The FDA has cleared Aptitude’s next-generation Metrix COVID Test, which the company says offers 3-fold higher sensitivity and 30% faster results compared to its EUA version.
A Columbia University study finds that combining plasma p-tau217 blood tests with APOE4 genotyping can predict Alzheimer’s symptom onset within three to four years in high-risk, asymptomatic individuals.
The Association for Diagnostics & Laboratory Medicine recommends that AI tools in clinical labs remain under existing CLIA oversight, citing the need for established validation and monitoring standards in response to a federal RFI.
The investigational PANXEON liquid biopsy detected early-stage pancreatic cancer with 87% sensitivity and low false-positive rates in a multi-center study of nearly 1,800 patients.
